James Tyree - ChemoCentryx Independent Director
| CCXIDelisted Stock | USD 51.99 0.00 0.00% |
Director
Mr. James L. Tyree is an Independent Director of ChemoCentryx, Inc., since June 5, 2012. Mr. Tyree has served as cofounder, chairman and managing partner of Tyree DAngelo Partners, a private equity investment firm. Prior to founding Tyree DAngelo Partners, Mr. Tyree was Executive Vice President and President of Abbott Biotech Ventures, a subsidiary of Abbott Laboratories focused on investments in early stage biotechnology companies. Prior to that, Mr. Tyree held numerous executive positions at Abbott, including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, Corporationrationrate Vice President Pharmaceutical and Nutritional Products Group Business Development and Divisional Vice President and General Manager, Japan. Prior to rejoining Abbott in 1997, Mr. Tyree was the President of SUGEN, Inc., and held management positions in BristolMyers Squibb, Pfizer and Abbott. Mr. Tyree currently serves as a director of Assertio Therapeutics, Inc since 2012.
| Age | 65 |
| Tenure | 12 years |
| Phone | 650 210-2910 |
| Web | www.chemocentryx.com |
ChemoCentryx Management Efficiency
The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 73.2 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. ChemoCentryx has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ChemoCentryx until it has trouble settling it off, either with new capital or with free cash flow. So, ChemoCentryx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ChemoCentryx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ChemoCentryx to invest in growth at high rates of return. When we think about ChemoCentryx's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Danforth Leitner | Visionary Education Technology | 78 | |
| Walter Isaacson | United Airlines Holdings | 65 | |
| James Whitehurst | United Airlines Holdings | 50 | |
| Joey Jacobs | Cumberland Pharmaceuticals | 63 | |
| Sito Pantoja | United Airlines Holdings | 61 | |
| Martin Cearnal | Cumberland Pharmaceuticals | 69 | |
| Tom Davis | Alphatec Holdings | 65 | |
| Barney Harford | United Airlines Holdings | 43 | |
| William Nuti | United Airlines Holdings | 53 | |
| Henry Meyer | United Airlines Holdings | 64 | |
| James Jones | Cumberland Pharmaceuticals | 67 | |
| Quentin Blackford | Alphatec Holdings | 39 | |
| Charles Yamarone | United Airlines Holdings | 55 | |
| Barnaby Harford | United Airlines Holdings | 46 | |
| Mortimer Berkowitz | Alphatec Holdings | 62 | |
| David Vitale | United Airlines Holdings | 71 | |
| lan Molson | Alphatec Holdings | 61 | |
| Todd Insler | United Airlines Holdings | 49 | |
| Robert Milton | United Airlines Holdings | 55 | |
| Stephen Appel | Visionary Education Technology | 64 | |
| James Kennedy | United Airlines Holdings | 64 | |
Management Performance
| Return On Equity | -46.96 | |||
| Return On Asset | -18.55 |
ChemoCentryx Leadership Team
Elected by the shareholders, the ChemoCentryx's board of directors comprises two types of representatives: ChemoCentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoCentryx. The board's role is to monitor ChemoCentryx's management team and ensure that shareholders' interests are well served. ChemoCentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoCentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Israel Charo, Senior Vice President - Research | ||
| Jan Hillson, Senior Vice President - Drug Development | ||
| Geoffrey Parker, Independent Director | ||
| Susan Kanaya, CFO, Sr. VP of Fin. and Secretary | ||
| Petrus Bekker, Senior Vice President - Clinical and Medical Affairs | ||
| Joseph Feczko, Independent Director | ||
| Markus Cappel, Chief Bus. Officer and Treasurer | ||
| William Fairey, COO, Executive Vice President | ||
| Thomas Edwards, Independent Director | ||
| James Tyree, Independent Director | ||
| Henry McKinnell, Director | ||
| Rajinder Singh, Senior Vice President - Research | ||
| Roger Lucas, Lead Independent Director | ||
| Rita Jain, Independent Director | ||
| Thomas Schall, Founder, Chairman, CEO and Pres |
ChemoCentryx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoCentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -46.96 | |||
| Return On Asset | -18.55 | |||
| Operating Margin | (353.17) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 70.03 M | |||
| Shares Owned By Insiders | 12.01 % | |||
| Shares Owned By Institutions | 84.39 % | |||
| Number Of Shares Shorted | 7.61 M | |||
| Price To Earning | 40.53 X | |||
| Price To Book | 10.04 X |
Pair Trading with ChemoCentryx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoCentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoCentryx will appreciate offsetting losses from the drop in the long position's value.Moving together with ChemoCentryx Stock
| 0.82 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.82 | NONOF | Novo Nordisk AS | PairCorr |
Moving against ChemoCentryx Stock
| 0.81 | WXIBF | WuXi Biologics | PairCorr |
| 0.8 | HNRC | Houston Natural Resources Earnings Call Next Week | PairCorr |
| 0.65 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.52 | CMXHF | CSL Limited | PairCorr |
| 0.49 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to ChemoCentryx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoCentryx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoCentryx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoCentryx to buy it.
The correlation of ChemoCentryx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoCentryx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoCentryx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoCentryx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in ChemoCentryx Stock
If you are still planning to invest in ChemoCentryx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ChemoCentryx's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |